metastatic/advanced hepatocellular cancer (mHCC) | ||
mHCC - (neo)adjuvant (NA) | mHCC - 1st line (L1) | |
nivolumab plus ipilimumab | NCI-2018-01106 | |
nivolumab plus ipilimumab plus SoC | CheckMate 9DW |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -